CurrentUnitedHealthcarePolicy 2026T0650F

Injectable Dermal Fillers and Bulking Agents

Defines UnitedHealthcare Commercial and Individual Exchange coverage positions for injectable dermal fillers (including Radiesse, Sculptra and others) and injectable bulking agents for vocal fold medialization, with criteria distinguishing reconstructive (medically necessary) versus cosmetic (not medically necessary) uses and applicability to FDA-labeled indications.

Policy Summary

PayerUnitedHealthcare

PolicyInjectable Dermal Fillers and Bulking Agents

Policy CodePolicy 2026T0650F

Change TypeTemplate Update

Effective DateJan 1, 2026

Next Review Date

Key ActionVerify member-specific benefits and prior authorization requirements and ensure medical record documentation supports the clinical criteria for coverage.

POLICY UPDATE CHANGES

Template Update noted in Policy History/Revision Information effective 01/01/2026

2Reconstructive for HIV facial lipoatrophy

All othersCosmetic / not medically necessary

FDA-labeledBulking agents coverage tied to FDA labeling

Coverage Summary

Scope: Defines UnitedHealthcare Commercial and Individual Exchange coverage positions for injectable dermal fillers (including Radiesse, Sculptra and others) and injectable bulking agents for vocal fold medialization, distinguishing reconstructive (medically necessary) versus cosmetic (not medically necessary) uses. Policy stance: mixed — some uses are covered (reconstructive/FDA‑indicated) and others are not (cosmetic). Effective/last review date: 01/01/2026.

Policy-level Facts

Policy Number2026T0650F

Effective DateJanuary 1, 2026

Last ReviewJanuary 1, 2026

Scope SummaryDefines UnitedHealthcare Commercial and Individual Exchange coverage positions for injectable dermal fillers (including Radiesse, Sculptra) and injectable bulking agents for vocal fold medialization; distinguishes reconstructive (medically necessary) uses such as HIV-related facial lipoatrophy and FDA-labeled vocal fold indications from cosmetic (not medically necessary) uses; includes applicable CPT and HCPCS codes and notes that member-specific plan determines final coverage.

Key points: Dermal fillers (Radiesse, Sculptra) are considered reconstructive and medically necessary when used to treat HIV‑related facial lipoatrophy, but are cosmetic and not medically necessary for other indications. Injectable bulking agents for vocal fold medialization are covered when use is consistent with FDA‑labeled indications, contraindications, warnings, and precautions.

Dermal Filler Injections - Medical Necessity

Dermal Filler Injections - Coverage Determinations

Covered when ALL of the following are met:

ALL of the following

ONE of
- Radiesse (calcium hydroxylapatite) used for treatment of facial defects due to facial lipoatrophy in individuals living with human immunodeficiency virus (HIV)
- Sculptra (poly-L-lactic acid) used for treatment of facial defects due to facial lipoatrophy in individuals living with HIV
Indication is facial lipoatrophy (facial fat loss) due to HIV infection

Injectable Bulking Agents - Medical Necessity

Injectable Bulking Agents - Coverage Determinations

Covered when ALL of the following are met:

ALL of the following

Injectable bulking agents are used for the treatment of vocal fold insufficiency/dysfunction
Use is consistent with U.S. Food and Drug Administration (FDA) labeled indications, contraindications, warnings, and precautions

Not Medically Necessary / Cosmetic Uses

Dermal Filler Injections - Not Medically Necessary

The following uses are NOT medically necessary:

ANY of the following

Radiesse and Sculptra for all indications other than facial lipoatrophy due to HIV (considered cosmetic and not medically necessary)
All other dermal filler products for any indication (considered cosmetic and not medically necessary)

Background evidence: Clinical trials, systematic reviews, and specialty society guidance support the covered uses — FDA‑approved fillers for HIV facial lipoatrophy and bulking agents for vocal fold medialization show benefit in symptom, quality‑of‑life, and voice outcome measures. Other dermal filler uses are considered cosmetic and not supported for coverage.

Coding

CPT / Procedure codes referencedCPT

31570	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic
31571	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic; with operating microscope or telescope
31574	Laryngoscopy, flexible; with injection(s) for augmentation (e.g., percutaneous, transoral), unilateral

HCPCS / Other supply/drug codes referencedHCPCS

G0429	Dermal Filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS) (e.g., as a result of highly active antiretroviral therapy)
L8607	Injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies
Q2026	Injection, Radiesse, 0.1 ml
Q2028	Injection, Sculptra, 0.5 mg

Note: Inclusion of procedure and supply codes in this policy does not guarantee reimbursement. Benefit coverage is determined by the member‑specific benefit plan and other billing or coverage policies may apply.

Provider Actions

Documentation Required

Medical record documentation required for reviews

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the service requested; refer to the guidelines titled Medical Records Documentation Used for Reviews.

Billing Rule

Code use guidance

The following CPT and HCPCS codes are listed in the policy for billing reference. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service, nor does inclusion guarantee reimbursement; other policies and the member-specific benefit plan may apply.

31570
31571
31574
G0429
L8607
Q2026
Q2028

Prior Authorization

Plan determination requirement

Coverage must be determined per the member-specific benefit plan and applicable laws; verify benefits and any prior authorization requirements per that plan before treatment.

Background & Evidence

FDA and clinical context: Radiesse and Sculptra are FDA‑approved to treat facial lipoatrophy in people with HIV. Injectable bulking agents have FDA clearance for vocal cord medialization. Use of these agents for the stated, FDA‑aligned indications is supported; other uses of dermal fillers are considered cosmetic.

Study/Source	Key Finding
Vallejo et al. 2018
Objective improvement in HIV-associated facial lipoatrophy in 53% of cases; autologous fat had lower costs
Jagdeo et al. 2015 (systematic review)
PLLA (Sculptra) assigned B-level recommendation; CaHA (Radiesse) assigned C-level for HIV facial lipoatrophy
FDA approvals (Sculptra, Radiesse)
FDA approved Sculptra (2004) and Radiesse (2006) for treatment of facial fat loss in people with HIV
Rosen et al. 2009 (vocal fold injection study)
Significant improvements in voice measures up to 12 months; 22% further treatment rate at 12 months

Facial lipoatrophy (FLA): Facial fat loss associated with HIV infection and HAART, leading to aesthetic and psychosocial consequences.

Vocal fold insufficiency: Condition where one or both vocal cords do not close properly, causing voice changes and aspiration risk.